Slow Capital Inc. Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Slow Capital Inc. increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,844 shares of the biopharmaceutical company’s stock after buying an additional 47 shares during the period. Regeneron Pharmaceuticals comprises approximately 1.8% of Slow Capital Inc.’s investment portfolio, making the stock its 14th largest holding. Slow Capital Inc.’s holdings in Regeneron Pharmaceuticals were worth $10,402,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. FMR LLC lifted its position in shares of Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after buying an additional 669,517 shares in the last quarter. Northern Trust Corp lifted its position in shares of Regeneron Pharmaceuticals by 3.3% during the 3rd quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock valued at $878,271,000 after buying an additional 34,326 shares in the last quarter. Morgan Stanley lifted its position in shares of Regeneron Pharmaceuticals by 2.7% during the 3rd quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock valued at $799,061,000 after buying an additional 25,792 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Regeneron Pharmaceuticals by 0.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 967,414 shares of the biopharmaceutical company’s stock valued at $796,142,000 after buying an additional 2,666 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $697,296,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.6 %

NASDAQ REGN traded up $14.47 during trading on Wednesday, hitting $908.61. The stock had a trading volume of 160,401 shares, compared to its average volume of 491,262. The company has a market capitalization of $99.73 billion, a PE ratio of 25.73, a PEG ratio of 2.62 and a beta of 0.11. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The firm has a 50 day moving average price of $955.94 and a 200 day moving average price of $890.45. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. Regeneron Pharmaceuticals’s revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the company posted $10.96 EPS. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.18 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on REGN. StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, April 12th. Bank of America raised their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a report on Friday, April 12th. Truist Financial restated a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Barclays raised their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $970.57.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the transaction, the director now directly owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the transaction, the director now owns 18,282 shares in the company, valued at approximately $17,953,838.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bonnie L. Bassler sold 827 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the completion of the transaction, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The disclosure for this sale can be found here. Insiders sold a total of 13,729 shares of company stock valued at $13,124,641 in the last three months. 8.83% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.